<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34477295</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1755-3768</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>100</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta ophthalmologica</Title>
          <ISOAbbreviation>Acta Ophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of CD146 attenuates retinal neovascularization via vascular endothelial growth factor receptor 2 signalling pathway in proliferative diabetic retinopathy.</ArticleTitle>
        <Pagination>
          <StartPage>e899</StartPage>
          <EndPage>e911</EndPage>
          <MedlinePgn>e899-e911</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/aos.15007</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the expression of CD146 and its role in proliferative diabetic retinopathy (PDR).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Enzyme linked immunosorbent assay was performed to analyse the expression and relationship of sCD146, vascular endothelial growth factor (VEGF), sVEGFR1 and sVEGFR2 in vitreous specimens from PDR and idiopathic epiretinal membranes (IERM) or idiopathic macular hole patients. The location of CD146 in ERMs was detected by immunofluorescence. The oxygen-induced retinopathy (OIR) mice model was established and the adeno-associated virus expressing a shRNA of CD146 (AAV1-shCD146-GFP) was administered via intravitreal injection. The effect of AAV1-shCD146-GFP was explored by immunofluorescence, Western blot and quantitative real-time PCR.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The levels of sCD146 in vitreous specimens from PDR patients and CD146 in retinas from OIR mice were significantly increased. Immunofluorescence showed that CD146 was co-located with CD31, VEGF, VEGFR1 and VEGFR2, respectively. Intravitreal injection of AAV1-shCD146-GFP could dramatically reduce the formation of neovascularization and non-perfusion area by inhibiting VEGFR2 phosphorylation.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results indicated that CD146 was involved in the development of retinal neovascularization via VEGFR2 pathway. Anti-CD146 may be an innovative or adjuvant therapy, which provides a new direction for the treatment of PDR and other ocular neovascular diseases.</AbstractText>
          <CopyrightInformation>© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Jianqiang</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-5651-1932</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Kaixuan</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Xiaoyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Yuxun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Boyu</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Qingjing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Shanshan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Xiaoling</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-5753-5100</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Acta Ophthalmol</MedlineTA>
        <NlmUniqueID>101468102</NlmUniqueID>
        <ISSNLinking>1755-375X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051929">CD146 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497902">MCAM protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C000588866">KDR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C000592875">Kdr protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051929" MajorTopicYN="N">CD146 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003930" MajorTopicYN="Y">Diabetic Retinopathy</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015861" MajorTopicYN="Y">Retinal Neovascularization</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040301" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014822" MajorTopicYN="N">Vitreous Body</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CD146</Keyword>
        <Keyword MajorTopicYN="N">angiogenesis</Keyword>
        <Keyword MajorTopicYN="N">proliferative diabetic retinopathy</Keyword>
        <Keyword MajorTopicYN="N">vascular endothelial growth factor receptor 2</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>8</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34477295</ArticleId>
        <ArticleId IdType="doi">10.1111/aos.15007</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Bardin N, Blot-Chabaud M, Despoix N et al. (2009): CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler Thromb Vasc Biol 29: 746-753.</Citation>
        </Reference>
        <Reference>
          <Citation>Bu P, Gao L, Zhuang J, Feng J, Yang D &amp; Yan X (2006): Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Mol Cancer Ther 5: 2872-2878.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen J, Luo Y, Hui H et al. (2017): CD146 coordinates brain endothelial cell-pericyte communication for blood-brain barrier development. Proc Natl Acad Sci USA 114: E7622-E7631.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheung N, Mitchell P &amp; Wong TY (2010): Diabetic retinopathy. Lancet 376: 124-136.</Citation>
        </Reference>
        <Reference>
          <Citation>Ciftci Dogansen S, Helvaci A, Adas M &amp; Deniz Onal S (2013): The relationship between early atherosclerosis and endothelial dysfunction in type 1 diabetic patients as evidenced by measurement of carotid intima-media thickness and soluble CD146 levels: a cross sectional study. Cardiovasc Diabetol 12: 153.</Citation>
        </Reference>
        <Reference>
          <Citation>Das A, McGuire PG &amp; Rangasamy S (2015): Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 122: 1375-1394.</Citation>
        </Reference>
        <Reference>
          <Citation>Ebrahimiadib N, Maleki A, Fadakar K, Manhapra A, Ghassemi F &amp; Foster CS (2021): Vascular abnormalities in uveitis. Surv Ophthalmol 66: 653-667.</Citation>
        </Reference>
        <Reference>
          <Citation>Hartnett ME, Baehr W &amp; Le YZ (2017): Diabetic retinopathy, an overview. Vision Res 139: 1-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Hollanders K, Hove IV, Sergeys J et al. (2017): AMA0428, a potent rock inhibitor, attenuates early and late experimental diabetic retinopathy. Curr Eye Res 42: 260-272.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu Y, Lu X, Xu Y et al. (2017): Salubrinal attenuated retinal neovascularization by inhibiting CHOP-HIF1alpha-VEGF pathways. Oncotarget 8: 77219-77232.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang T, Zhuang J, Duan H et al. (2012): CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 120: 2330-2339.</Citation>
        </Reference>
        <Reference>
          <Citation>Joshkon A, Heim X, Dubrou C et al. (2020): Role of CD146 (MCAM) in physiological and pathological angiogenesis-contribution of new antibodies for therapy. Biomedicines 8: 633.</Citation>
        </Reference>
        <Reference>
          <Citation>Jouve N, Bachelier R, Despoix N et al. (2015): CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation. Int J Cancer 137: 50-60.</Citation>
        </Reference>
        <Reference>
          <Citation>Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G &amp; Johnson JP (1987): Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47: 841-845.</Citation>
        </Reference>
        <Reference>
          <Citation>Leroyer AS, Blin MG, Bachelier R, Bardin N, Blot-Chabaud M &amp; Dignat-George F (2019): CD146 (cluster of differentiation 146). Arterioscler Thromb Vasc Biol 39: 1026-1033.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Y, Yang Z, Lai P, Huang Z, Sun X, Zhou T, He C &amp; Liu X (2020): Bcl-6-directed follicular helper T cells promote vascular inflammatory injury in diabetic retinopathy. Theranostics 10: 4250-4264.</Citation>
        </Reference>
        <Reference>
          <Citation>Qian YN, Luo YT, Duan HX, Feng LQ, Bi Q, Wang YJ &amp; Yan XY (2014): Adhesion molecule CD146 and its soluble form correlate well with carotid atherosclerosis and plaque instability. CNS Neurosci Ther 20: 438-445.</Citation>
        </Reference>
        <Reference>
          <Citation>Saito T, Saito O, Kawano T, Tamemoto H, Kusano E, Kawakami M &amp; Ishikawa SE (2007): Elevation of serum adiponectin and CD146 levels in diabetic nephropathy. Diabetes Res Clin Pract 78: 85-92.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R &amp; D'Amore PA (1994): Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111.</Citation>
        </Reference>
        <Reference>
          <Citation>Stalin J, Harhouri K, Hubert L et al. (2016): Soluble CD146 boosts therapeutic effect of endothelial progenitors through proteolytic processing of short CD146 isoform. Cardiovasc Res 111: 240-251.</Citation>
        </Reference>
        <Reference>
          <Citation>Stitt AW, Curtis TM, Chen M et al. (2016): The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res 51: 156-186.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang D, Duan H, Feng J et al. (2020a): Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction. Theranostics 10: 231-246.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang P, Luo Y, Duan H et al. (2013): MicroRNA 329 suppresses angiogenesis by targeting CD146. Mol Cell Biol 33: 3689-3699.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang T, Tsirukis DI &amp; Sun Y (2020b): Targeting neuroinflammation in neovascular retinal diseases. Front Pharmacol 11: 234.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu JH, Li YN, Chen AQ et al. (2020): Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Mol Med 12: e10154.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu Y, Cheng Q, Yang B, Yu S, Xu F, Lu L &amp; Liang X (2015): Increased sCD200 levels in vitreous of patients with proliferative diabetic retinopathy and its correlation with VEGF and proinflammatory cytokines. Invest Ophthalmol Vis Sci 56: 6565-6572.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu Y, Lu X, Hu Y, Yang B, Tsui CK, Yu S, Lu L &amp; Liang X (2018): Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1alpha-VEGF pathway in oxygen-induced retinopathy mice. J Pineal Res 64: e12473.</Citation>
        </Reference>
        <Reference>
          <Citation>Yan X, Lin Y, Yang D et al. (2003): A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102: 184-191.</Citation>
        </Reference>
        <Reference>
          <Citation>Zeng Q, Wu Z, Duan H et al. (2014): Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice. Protein Cell 5: 445-456.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
